Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

PURPOSE: Patients with chronic lymphocytic leukemia (CLL) with high-risk genomic features achieve poor outcomes with traditional therapies. A phase I study of a pharmacokinetically derived schedule of flavopiridol suggested promising activity in CLL, irrespective of high-risk features. Given the rel...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Lin, Thomas S., Ruppert, Amy S., Johnson, Amy J., Fischer, Beth, Heerema, Nyla A., Andritsos, Leslie A., Blum, Kristie A., Flynn, Joseph M., Jones, Jeffrey A., Hu, Weihong, Moran, Mollie E., Mitchell, Sarah M., Smith, Lisa L., Wagner, Amy J., Raymond, Chelsey A., Schaaf, Larry J., Phelps, Mitch A., Villalona-Calero, Miguel A., Grever, Michael R., Byrd, John C.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2009
Aiheet:
Original Reports
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2793044/
https://ncbi.nlm.nih.gov/pubmed/19826119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.6944
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia